INTRAPERITONEAL VERSUS INTRAVENOUS CHEMOTHERAPY: TREATING OVARIAN CANCER

Emilija Kurlytė1, Skaistė Tulytė2

1 Faculty of Medicine, Vilnius University, Lithuania

2 Vilnius University Hospital Santariskiu Klinikos, Centre of Hematology, Oncology and Transfusion Med.

Ovarian cancer is characterized as aggressive and usually asymptomatic disease therefore is diagnosed at late-stage, so it is important to look for the best treatment [1]. One promising way is intraperitoneal (IP) chemotherapy. Some studies have demonstrated its survival advantage in comparison to intravenous (IV), although more severe adverse effects have been noticed and it is unknown if it is long-term beneficial [2].

Our aim was to compare outcomes of IP and IV chemotherapy, progression-free survival (PFS) and side effects of drugs.

Methods we used: retrospective study of 36 patients with epithelial ovarian cancer at Vilnius University Hospital Santariskiu Klinikos. 15/36 patients were treated with IP chemotherapy and 21/36 – IV. Analyzed data: demography of patients, cytoreduction rate, tumor differentiation grade, existence of metastasis, influence of neoadjuvant chemotherapy, PFS and drugs' adverse effects. Associations between categorical variables were determined using Shapiro-Wilk test, t-test of independent samples; applications used – Microsoft Excel 2010, SPSS 17.0.

Results: average age of patients: IP – $47.5\pm7.9$ years, IV – $52.8\pm12.4$ years.

Table 1. Average PFS values in both groups, regarding different factors.
IP (months)IV (months)p=
Statistically significantAverage PFS with neoadjuvant chemotherapy13.3±2.521.5±10.70.001
Average PFS19.5±2.920.1±4.00.904
PFS after radical debulking (R0)13,3±2,523,1±9,30.679
No statistical significancePFS after G3 differentiation grade21.8±4.719.3±4.10.694
PFS if metastatic disease1213.6±1.8-
PFS with no neoadjuvant chemotherapy28.8±4.219.6±4.10.133

To sum up: based on results, there were no statistical significance in both patient's groups average PFS, although treatment starting with neoadjuant chemotherapy is better with IV. Both ways are well tolerated, we did not observe extremely severe side effects.

Table 2. Side effects of chemotherapeutic drugs.
More often IPMore often IVSimilar frequency
IP (%)IV (%)IP (%)IV (%)IP (%)IV (%)
Drug induced polyneuropathy53.333.3Anemia46.771.4Cardiotoxicity26.723.8
Neutropenia53.347.6Thrombocytopenia13.357.1Nephrotoxicity6.79.5
Obstipation26.74.8Hepatotoxicity023.8Postoperative adhesions6.79.5
Dyspepsia46.728.6Arthralgia014.3Insomnia6.59.5
Weakness20.09.5Rash09.5
Abdominal pain13.30Ototoxicity04.8
Infection at drain site13.30Anaphylaxis04.8
Headache04.8

[1] Chan JK, Cheung MK, Husain A, et al: Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol 108:521-528 (2006)

[2] Tewari D, Java JJ, Salani R, Armstrong DK, Markman M, Herzog T,Bradley et al: Long-Term Survival Advantage and prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study. Journal of Clinical Oncology 33: 1460 (2015)